This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Exscientia and Recursion Enter Definitive Agreement

Exscientia and Recursion Enter Definitive Agreement

13 Aug 2024

Recursion and Exscientia plc have announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Chris Gibson, Co-Founder and CEO of Recursion as well as... Read more

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

20 Jun 2023

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform,... Read more

Professor Tom Brown is winner of the RSC's 2023 Chemistry Biology Interface open Prize: Khorana Prize

Professor Tom Brown is winner of the RSC's 2023 Chemistry Biology Interface open Prize: Khorana Prize

14 Jun 2023

Professor Tom Brown is winner of the RSC's 2023 Chemistry Biology Interface open Prize: Khorana Prize Professor Tom Brown CChem FRSC of the University of Oxford has been awarded a research and innovation prize by the Royal Society of Chemistry for his major contributions in the nucleic acid field, including the synthesis of biocompatible artificial DNA, and molecular tools for genetic analysis and diagnostics. In addition to his academic... Read more

OXFORD NANOPORE TECHNOLOGIES PLC - National German rare disease study

OXFORD NANOPORE TECHNOLOGIES PLC - National German rare disease study

12 Jun 2023

National German rare disease study Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces a research collaboration agreement with the 'Clinical Long-read Genome Initiative' (lonGER), a new national German programme developed to evaluate the clinical and research applications of comprehensive nanopore-based sequencing to advance... Read more

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

02 Jun 2023

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting Scancell Holdings plc ("Scancell" or the "Company") Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting ModiFY trial progressing through monotherapy expansion cohorts and combination... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More